These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27376368)

  • 21. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic.
    Li GQ; Yuan M; Yang XY; Li CR; Hu XX; Zhang WX; Lou RH; Guo HY; You XW; Cen S; Jiang JD; You XF
    Chemotherapy; 2012; 58(3):175-84. PubMed ID: 22699239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and antibacterial activity of the C-7 side chain of 3-aminoquinazolinediones.
    Hutchings KM; Tran TP; Ellsworth EL; Watson BM; Sanchez JP; Showalter HD; Stier MA; Shapiro M; Themis Joannides E; Huband M; Nguyen DQ; Maiti S; Li T; Tailor J; Thomas G; Ha C; Singh R
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5087-90. PubMed ID: 18752951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK; Liu EY; Cheng AF
    Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis, and in vitro antibacterial activity of fluoroquinolone derivatives containing a chiral 3-(alkoxyimino)-2-(aminomethyl)azetidine moiety.
    Lv K; Sun Y; Sun L; Wei Z; Guo H; Wu J; Liu M
    ChemMedChem; 2012 Jul; 7(7):1230-6. PubMed ID: 22639240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria.
    Kerns RJ; Rybak MJ; Cheung CM
    Diagn Microbiol Infect Dis; 2006 Apr; 54(4):305-10. PubMed ID: 16466892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Change in hydrophilicity of penicillins during advanced oxidation by radiolytically generated OH compromises the elimination of selective pressure on bacterial strains.
    Szabó L; Tóth T; Engelhardt T; Rácz G; Mohácsi-Farkas C; Takács E; Wojnárovits L
    Sci Total Environ; 2016 May; 551-552():393-403. PubMed ID: 26881730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
    Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Food-grade antimicrobials potentiate the antibacterial activity of 1,2-hexanediol.
    Yogiara ; Hwang SJ; Park S; Hwang JK; Pan JG
    Lett Appl Microbiol; 2015 May; 60(5):431-9. PubMed ID: 25631558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levofloxacin oxidation by ozone and hydroxyl radicals: kinetic study, transformation products and toxicity.
    Hamdi El Najjar N; Touffet A; Deborde M; Journel R; Leitner NK
    Chemosphere; 2013 Oct; 93(4):604-11. PubMed ID: 23850240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis on susceptibility of ocular bacterial pathogens to four kinds of fluoroquinolone].
    Wang ZQ; Li L; Li R; Luo SY; Bai XQ; Liang QF; Deng SJ; Sun XG
    Zhonghua Yan Ke Za Zhi; 2008 Mar; 44(3):233-6. PubMed ID: 18785547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.
    Kwon AR; Min YH; Ryu JM; Choi DR; Shim MJ; Choi EC
    J Antimicrob Chemother; 2006 Sep; 58(3):684-8. PubMed ID: 16873394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and in vitro antibacterial activity of 7-(4-alkoxyimino-3-amino-3-methylpiperidin-1-yl)fluoroquinolone derivatives.
    Chai Y; Wan ZL; Wang B; Guo HY; Liu ML
    Eur J Med Chem; 2009 Oct; 44(10):4063-9. PubMed ID: 19481308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of gatifloxacin tested against isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (North America, 1998-2003).
    Fedler KA; Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2006 Jun; 55(2):157-64. PubMed ID: 16529904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and evaluation of clinafloxacin triazole hybrids as a new type of antibacterial and antifungal agents.
    Wang Y; Damu GL; Lv JS; Geng RX; Yang DC; Zhou CH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5363-6. PubMed ID: 22884108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA-interaction and in vitro antimicrobial studies of some mixed-ligand complexes of cobalt(II) with fluoroquinolone antibacterial agent ciprofloxacin and some neutral bidentate ligands.
    Patel MN; Chhasatia MR; Gandhi DS
    Bioorg Med Chem Lett; 2009 May; 19(10):2870-3. PubMed ID: 19359174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics.
    Domhan C; Uhl P; Meinhardt A; Zimmermann S; Kleist C; Lindner T; Leotta K; Mier W; Wink M
    Int J Antimicrob Agents; 2018 Jul; 52(1):52-62. PubMed ID: 29649587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gatifloxacin.
    Perry CM; Barman Balfour JA; Lamb HM
    Drugs; 1999 Oct; 58(4):683-96; discussion 697-8. PubMed ID: 10551438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.